Biocept, Inc. (BIOC) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Biocept, Inc. (NASDAQ:BIOC) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $2.50.
A number of research firms have commented on BIOC. Westpark Capital reaffirmed an “outperform” rating on shares of Biocept in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of Biocept from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine lowered shares of Biocept from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Shares of Biocept (NASDAQ:BIOC) opened at $0.89 on Monday. The company has a quick ratio of 2.02, a current ratio of 2.13 and a debt-to-equity ratio of 0.13. Biocept has a fifty-two week low of $0.74 and a fifty-two week high of $3.39.
Biocept (NASDAQ:BIOC) last released its earnings results on Thursday, August 10th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. The business had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.23 million. research analysts expect that Biocept will post -0.77 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Biocept stock. Creative Planning boosted its stake in Biocept, Inc. (NASDAQ:BIOC) by 64,679.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,811 shares of the medical research company’s stock after acquiring an additional 246,430 shares during the quarter. Creative Planning owned 0.93% of Biocept worth $338,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 7.79% of the company’s stock.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.